EMAIL THIS PAGE TO A FRIEND

Oncotarget

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors.


PMID 29221116

Abstract

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma.